Related Experiment Video
Updated: Jan 27, 2026
Orthotopic Mouse Model of Colorectal Cancer
Published on: December 4, 2007
Targeting siRNA in colorectal cancer therapy: Nanotechnology comes into view
Shahin Aghamiri1, Ali Jafarpour2, Ziba Veisi Malekshahi3
1Student Research Committee, Department of Medical Biotechnology, School of Advanced Technology in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Colorectal cancer (CRC) is known as one of the most important causes of death and mortality worldwide. Although several efforts have been made for finding new therapies, no achievements have been made in this area. Multidrug resistance (MDR) mechanisms are one of the key factors that could lead to the failure of chemotherapy. Moreover, it has been shown that various chemotherapy drugs are associated with several side effects. Hence, it seems that finding new drugs or new therapeutic platforms is required. Among different therapeutic approaches, utilization of nanoparticles (NPs) for targeting a variety of molecules such as siRNAs are associated with good results for the treatment of CRC. Targeting siRNA-mediated NPs could turn off the effects of oncogenes and MDR-related genes. In the current study, we summarized various siRNAs targeted by NPs which could be used for the treatment of CRC. Moreover, we highlighted other routes such as liposome for targeting siRNAs in CRC therapy.
Insights
New nanoparticle (NP) therapies show promise for colorectal cancer (CRC) treatment by targeting oncogenes and multidrug resistance (MDR) genes with small interfering RNAs (siRNAs). This approach offers a potential alternative to conventional chemotherapy, addressing treatment failures and side effects.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Colorectal cancer (CRC) remains a leading cause of cancer mortality globally.
- Chemotherapy failure due to multidrug resistance (MDR) and significant side effects necessitate novel therapeutic strategies.
- Current treatment limitations highlight the urgent need for innovative drugs and delivery platforms.
Purpose of the Study:
- To review the application of nanoparticle (NP)-mediated delivery of small interfering RNAs (siRNAs) for colorectal cancer (CRC) treatment.
- To explore the potential of targeting oncogenes and MDR-related genes using siRNA-loaded NPs in CRC therapy.
- To discuss alternative delivery systems, such as liposomes, for siRNA-based CRC treatment.
Main Methods:
- Literature review of studies investigating nanoparticle-based siRNA delivery systems for CRC.
- Analysis of mechanisms by which targeted siRNAs can inhibit oncogenes and MDR-related genes.
- Examination of liposomal delivery systems as a potential route for siRNA therapeutics in CRC.
Main Results:
- Nanoparticle-mediated siRNA delivery demonstrates efficacy in targeting key genes involved in CRC progression and chemoresistance.
- Targeting oncogenes and MDR genes with siRNAs via NPs can potentially overcome treatment failures.
- Liposomes represent a viable alternative platform for delivering siRNAs in CRC therapy.
Conclusions:
- Nanoparticle-based siRNA delivery offers a promising therapeutic strategy for colorectal cancer, addressing limitations of conventional chemotherapy.
- Targeting specific genes with siRNAs delivered via NPs can effectively combat CRC and overcome multidrug resistance.
- Further research into NP and liposomal delivery systems is warranted to advance siRNA-based CRC treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Econometric Views (EViews)
01:27Cranial Bones: Lateral View
The temporal bone forms the lower lateral side of the skull. The temporal bone is subdivided into several regions. The flattened upper portion is the squamous portion of the temporal bone. Below this area and projecting anteriorly is the zygomatic process of the temporal bone, which forms the posterior portion of the zygomatic arch. Posteriorly is the mastoid portion of the temporal bone. Projecting...
02:30Small interfering RNAs (siRNA)